Literature DB >> 9728569

Combination drug therapy for cryptosporidiosis in AIDS.

N H Smith1, S Cron, L M Valdez, C L Chappell, A C White.   

Abstract

Aside from effective antiretroviral therapy, there is no consistently effective antiparasitic therapy for cryptosporidiosis in AIDS. The purpose of this study was to assess safety, efficacy, and durability of combination therapy with paromomycin and azithromycin for chronic cryptosporidiosis. Patients with AIDS, chronic cryptosporidiosis, and < 100 CD4 cells/microL were treated with open-label paromomycin (1.0 g twice a day) plus azithromycin (600 mg once a day) for 4 weeks, followed by paromomycin alone for 8 weeks. In 11 patients, median stool frequency decreased from 6.5/day (baseline) to 4.9/day (week 4) and 3.0/day (week 12). Median reductions in 24-h oocyst excretion were 84%, 95%, and >99% at 2, 4, and 12 weeks, respectively. None of the responses were attributable to antiretrovirals. Of 5 survivors at 12-30 months of follow-up, 3 remain asymptomatic off medications, and 2 have chronic, mild diarrhea. Treatment of cryptosporidiosis with azithromycin and paromomycin was associated with significant reduction in oocyst excretion and some clinical improvement.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9728569     DOI: 10.1086/515352

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  21 in total

1.  Oral nitazoxanide and paromomycin inhalation for systemic cryptosporidiosis in a patient with AIDS.

Authors:  X de la Tribonnière; M Valette; S Alfandari
Journal:  Infection       Date:  1999 May-Jun       Impact factor: 3.553

2.  Polymerase chain reaction for Cryptosporidium in the immunocompromised host.

Authors:  Luis Ignacio Gonzalez-Granado
Journal:  Pediatr Nephrol       Date:  2009-11-10       Impact factor: 3.714

3.  Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.

Authors:  George K Siberry; Mark J Abzug; Sharon Nachman; Michael T Brady; Kenneth L Dominguez; Edward Handelsman; Lynne M Mofenson; Steve Nesheim
Journal:  Pediatr Infect Dis J       Date:  2013-11       Impact factor: 2.129

4.  Molecular genotyping of human cryptosporidiosis in Northern Ireland: epidemiological aspects and review.

Authors:  C J Lowery; B C Millar; J E Moore; J Xu; L Xiao; P J Rooney; L Crothers; J S Dooley
Journal:  Ir J Med Sci       Date:  2001 Oct-Dec       Impact factor: 1.568

5.  A probable means to an end: exploring P131 pharmacophoric scaffold to identify potential inhibitors of Cryptosporidium parvum inosine monophosphate dehydrogenase.

Authors:  Kehinde F Omolabi; Emmanuel A Iwuchukwu; Clement Agoni; Fisayo A Olotu; Mahmoud E S Soliman
Journal:  J Mol Model       Date:  2021-01-09       Impact factor: 1.810

Review 6.  Gastrointestinal manifestations of HIV infection.

Authors:  M R Wallace; O S Brann
Journal:  Curr Gastroenterol Rep       Date:  2000-08

Review 7.  Treatment of cryptosporidiosis in immunocompromised individuals: systematic review and meta-analysis.

Authors:  I Abubakar; S H Aliyu; C Arumugam; N K Usman; P R Hunter
Journal:  Br J Clin Pharmacol       Date:  2007-03-01       Impact factor: 4.335

Review 8.  New insights into human cryptosporidiosis.

Authors:  D P Clark
Journal:  Clin Microbiol Rev       Date:  1999-10       Impact factor: 26.132

9.  Case Report: Diagnosis of Cryptosporidiosis in Renal Transplantation in a Low-Prevalence Setting.

Authors:  Shuwei Zheng; Kwan Ki Karrie Ko; Kian Sing Chan; Indumathi Venkatachalam
Journal:  Am J Trop Med Hyg       Date:  2019-01       Impact factor: 2.345

10.  Treatment of Cryptosporidium: What We Know, Gaps, and the Way Forward.

Authors:  Hayley Sparks; Gayatri Nair; Alejandro Castellanos-Gonzalez; A Clinton White
Journal:  Curr Trop Med Rep       Date:  2015-08-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.